Rhythm Pharmaceuticals (RYTM) Revenue (2021 - 2026)

Rhythm Pharmaceuticals (RYTM) has 6 years of Revenue data on file, last reported at $60.1 million in Q1 2026.

• Quarterly Revenue rose 83.81% year-over-year to $60.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $217.2 million (up 58.67% YoY) and the FY2025 annual result came in at $189.8 million, up 45.83% from the prior year.
• Revenue climbed to $60.1 million in Q1 2026 per RYTM's latest filing, from $57.3 million in the prior quarter.
• Across five years, Revenue topped out at $60.1 million in Q1 2026 and bottomed at -$8.0 million in Q4 2022.
• The 5-year median for Revenue is $26.0 million (2024), against an average of $27.3 million.
• Peak annual rise in Revenue reached 4180.0% in 2022, while the deepest fall reached 542.93% in 2022.
• Tracing RYTM's Revenue over 5 years: stood at -$8.0 million in 2022, then soared by 401.12% to $24.2 million in 2023, then soared by 72.61% to $41.8 million in 2024, then surged by 36.87% to $57.3 million in 2025, then increased by 4.99% to $60.1 million in 2026.
• Per Business Quant, the three latest RYTM Revenue figures stand at $60.1 million (Q1 2026), $57.3 million (Q4 2025), and $51.3 million (Q3 2025).

Peer Comparison